JP2018514199A5 - - Google Patents

Download PDF

Info

Publication number
JP2018514199A5
JP2018514199A5 JP2017552966A JP2017552966A JP2018514199A5 JP 2018514199 A5 JP2018514199 A5 JP 2018514199A5 JP 2017552966 A JP2017552966 A JP 2017552966A JP 2017552966 A JP2017552966 A JP 2017552966A JP 2018514199 A5 JP2018514199 A5 JP 2018514199A5
Authority
JP
Japan
Prior art keywords
replicable
transgene
oncolytic virus
adenovirus
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017552966A
Other languages
English (en)
Japanese (ja)
Other versions
JP6931229B2 (ja
JP2018514199A (ja
Filing date
Publication date
Priority claimed from GBGB1507419.8A external-priority patent/GB201507419D0/en
Priority claimed from GBGB1516936.0A external-priority patent/GB201516936D0/en
Priority claimed from GBGB1522013.0A external-priority patent/GB201522013D0/en
Priority claimed from PCT/EP2016/059609 external-priority patent/WO2016174200A1/en
Application filed filed Critical
Priority to JP2018041788A priority Critical patent/JP6928380B2/ja
Publication of JP2018514199A publication Critical patent/JP2018514199A/ja
Publication of JP2018514199A5 publication Critical patent/JP2018514199A5/ja
Priority to JP2021129196A priority patent/JP7162929B2/ja
Publication of JP6931229B2 publication Critical patent/JP6931229B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017552966A 2015-04-30 2016-04-29 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス Active JP6931229B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2018041788A JP6928380B2 (ja) 2015-04-30 2018-03-08 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス
JP2021129196A JP7162929B2 (ja) 2015-04-30 2021-08-05 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1507419.8A GB201507419D0 (en) 2015-04-30 2015-04-30 Virus
GB1507419.8 2015-04-30
GB1516936.0 2015-09-24
GBGB1516936.0A GB201516936D0 (en) 2015-09-24 2015-09-24 Virus
GB1522013.0 2015-12-14
GBGB1522013.0A GB201522013D0 (en) 2015-12-14 2015-12-14 Virus
PCT/EP2016/059609 WO2016174200A1 (en) 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a b7 protein

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2018041788A Division JP6928380B2 (ja) 2015-04-30 2018-03-08 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス
JP2021129196A Division JP7162929B2 (ja) 2015-04-30 2021-08-05 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス

Publications (3)

Publication Number Publication Date
JP2018514199A JP2018514199A (ja) 2018-06-07
JP2018514199A5 true JP2018514199A5 (https=) 2019-06-06
JP6931229B2 JP6931229B2 (ja) 2021-09-01

Family

ID=56008588

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017552966A Active JP6931229B2 (ja) 2015-04-30 2016-04-29 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス
JP2018041788A Active JP6928380B2 (ja) 2015-04-30 2018-03-08 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス
JP2021129196A Active JP7162929B2 (ja) 2015-04-30 2021-08-05 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018041788A Active JP6928380B2 (ja) 2015-04-30 2018-03-08 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス
JP2021129196A Active JP7162929B2 (ja) 2015-04-30 2021-08-05 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス

Country Status (31)

Country Link
US (6) US11000559B2 (https=)
EP (2) EP3288573B1 (https=)
JP (3) JP6931229B2 (https=)
KR (4) KR20250134212A (https=)
CN (2) CN108396015B (https=)
AU (3) AU2016256582B2 (https=)
BR (2) BR112017023171A2 (https=)
CA (1) CA2984038C (https=)
CL (2) CL2017002731A1 (https=)
CO (1) CO2017010831A2 (https=)
CY (1) CY1122833T1 (https=)
DK (1) DK3288573T3 (https=)
EA (1) EA037611B1 (https=)
ES (1) ES2780366T3 (https=)
HR (1) HRP20200439T1 (https=)
HU (1) HUE048320T2 (https=)
IL (3) IL284375B (https=)
LT (1) LT3288573T (https=)
MX (1) MX2017013684A (https=)
MY (1) MY183703A (https=)
PE (2) PE20180241A1 (https=)
PH (1) PH12017501942A1 (https=)
PL (1) PL3288573T3 (https=)
PT (1) PT3288573T (https=)
RS (1) RS60105B1 (https=)
SA (2) SA517390260B1 (https=)
SG (3) SG11201708604TA (https=)
SI (1) SI3288573T1 (https=)
SM (1) SMT202000222T1 (https=)
WO (1) WO2016174200A1 (https=)
ZA (1) ZA201801589B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2671558C2 (ru) 2013-06-14 2018-11-02 Псайоксус Терапьютикс Лимитед Режим введения и составы для аденовирусов типа в
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
AU2014338864C1 (en) 2013-10-25 2020-07-16 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
PE20180241A1 (es) 2015-04-30 2018-01-31 Psioxus Therapeutics Ltd Adenovirus oncolitico que codifica una proteina b7
AU2016350701B2 (en) 2015-11-02 2021-08-19 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
EA201891022A1 (ru) * 2015-12-17 2019-01-31 Псайоксус Терапьютикс Лимитед Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
EP3436591B1 (en) * 2016-03-31 2023-01-04 The European Molecular Biology Laboratory Adenoviral coat protein derived delivery vehicles
CN119614520A (zh) 2016-08-29 2025-03-14 阿卡米斯生物公司 携带双特异性t细胞衔接器的腺病毒
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP4282969A3 (en) * 2016-09-02 2024-01-31 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
EP4023233B1 (en) * 2016-09-27 2026-01-07 Sator Therapeutics LLC Optimized oncolytic viruses and uses thereof
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
US12350303B2 (en) * 2017-02-03 2025-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Oncolytic virus therapy
WO2018201014A1 (en) 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
WO2018218151A1 (en) * 2017-05-25 2018-11-29 University Of Central Florida Research Foundation, Inc. Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
CA3064863A1 (en) 2017-05-26 2018-11-29 Epicentrx, Inc. Recombinant adenoviruses carrying transgenes
PL3630143T3 (pl) 2017-06-01 2023-10-30 Akamis Bio Limited Wirus onkolityczny i sposób
WO2019147921A1 (en) * 2018-01-26 2019-08-01 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
WO2019173334A1 (en) * 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
CN118001307A (zh) * 2018-03-30 2024-05-10 藤堂具纪 肿胀发生抑制型溶瘤病毒
CN119955743A (zh) * 2018-09-10 2025-05-09 上海锦斯生物技术有限公司 修饰的溶瘤病毒、其组合物和用途
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
AU2020232264B2 (en) * 2019-03-05 2026-02-19 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
US20220249127A1 (en) * 2019-05-14 2022-08-11 Oncolys Biopharma Inc. Method for administering oncolytic virus to tumor tissue, and device for administration
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
GB202102049D0 (en) * 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2022252185A1 (zh) * 2021-06-03 2022-12-08 上海允英生物医药科技有限公司 溶瘤病毒载体及其应用
EP4404947A4 (en) 2021-09-23 2025-12-10 Sagittarius Bio Inc Adenovirus and Methods of Using Adenovirus
US20250215452A1 (en) * 2022-03-25 2025-07-03 Universität Zürich Adenoviral Mediated Targeting of Activated Immune Cells
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
BR9405507A (pt) 1993-07-13 1999-05-25 Rhone Poulenc Rorer Sa Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
ATE374821T1 (de) 1997-02-20 2007-10-15 Univ Johns Hopkins Med Mutationen in atp-abhängigen transpositionsproteinen die die zielortspezifität reduzieren
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
EP1112372A1 (en) 1998-09-11 2001-07-04 Genvec, Inc. Alternatively targeted adenovirus
EP1137792B9 (en) 1998-12-09 2007-12-12 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
ATE519855T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus des serotyps ad11
AU5464000A (en) 1999-06-01 2000-12-18 University Of Washington Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
DE60115600T2 (de) * 2000-01-21 2006-07-20 Biovex Ltd. Virusstämme für die onkolytische behandlung von krebs
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
AU2001265154A1 (en) 2000-05-31 2001-12-11 Genvec, Inc. Method and composition for targeting an adenoviral vector
ATE449859T1 (de) 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie
US20050175589A1 (en) 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
WO2003064666A1 (en) * 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
AU2003223775A1 (en) 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
CN1705740B (zh) * 2002-10-15 2013-07-24 佩尔·松内·霍尔姆 具有反向基因表达的腺病毒及其应用
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
WO2004087930A1 (en) 2003-03-28 2004-10-14 Saint Louis University Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
AU2004260044B2 (en) 2003-07-18 2009-04-23 Onyx Pharmaceuticals, Inc. Subgroup B adenoviral vectors for treating disease
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
US7510868B2 (en) 2004-05-26 2009-03-31 Paul Harden Chimeric adenoviruses for use in cancer treatment
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
CN101068933A (zh) * 2004-08-25 2007-11-07 细胞基因系统有限公司 用于肿瘤细胞增强转导的纤维修饰的腺病毒载体
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
WO2006060314A2 (en) 2004-12-01 2006-06-08 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
AU2006284756B2 (en) 2005-08-31 2012-06-07 Genvec, Inc. Adenoviral vector-based malaria vaccines
DE102005055128B4 (de) 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
JP5448840B2 (ja) 2006-12-22 2014-03-19 プシオクサス・セラピューティクス・リミテッド 腫瘍退縮アデノウイルスの作出およびその使用
MX339014B (es) 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
CN101381742A (zh) 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20120283318A1 (en) * 2009-10-05 2012-11-08 Mei Ya-Fang Replicating viral vectors for gene therapy
WO2012024351A2 (en) 2010-08-16 2012-02-23 Salk Institute For Biological Studies Adenoviral assembly method
RU2013118724A (ru) * 2010-09-24 2014-10-27 Онкос Терапьютикс Ой Онколитические аденовирусные векторы и связанные с ними способы и применения
KR20130108371A (ko) 2010-09-24 2013-10-02 온코스 테라퓨틱스 오와이 단클론 항―ｃｔｌａ－４ 항체를 암호화하는 종양분해 아데노바이러스 벡터
US20140316369A1 (en) 2011-11-14 2014-10-23 Regenerative Sciences, Llc Suspended particle delivery systems and methods
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
AU2014338864C1 (en) 2013-10-25 2020-07-16 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
CA2931322A1 (en) 2013-11-22 2015-05-28 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) * 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
CN121592718A (zh) 2015-03-17 2026-03-03 倾斜生物医疗公司 编码双特异性抗体的溶瘤腺病毒及与其相关的方法和用途
PE20180241A1 (es) 2015-04-30 2018-01-31 Psioxus Therapeutics Ltd Adenovirus oncolitico que codifica una proteina b7
EA201891022A1 (ru) 2015-12-17 2019-01-31 Псайоксус Терапьютикс Лимитед Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
US20210198689A1 (en) 2016-03-18 2021-07-01 Nant Holdings Ip, Llc Multimodal Vector for Dendritic Cell Infection
CN119614520A (zh) 2016-08-29 2025-03-14 阿卡米斯生物公司 携带双特异性t细胞衔接器的腺病毒
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CA3040296A1 (en) 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
PL3630143T3 (pl) * 2017-06-01 2023-10-30 Akamis Bio Limited Wirus onkolityczny i sposób
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Similar Documents

Publication Publication Date Title
JP2018514199A5 (https=)
Sharma et al. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
CN105307671B (zh) 增强过继细胞疗法
US20220162279A1 (en) Combination immunotherapy
JP2018139586A5 (https=)
Homey et al. Chemokines: agents for the immunotherapy of cancer?
TWI850282B (zh) 用於治療癌症之質體建構體和使用方法
JP2024096876A (ja) 一本鎖および多鎖キメラポリペプチドならびにその使用方法
Sandau et al. IL-15 regulates both quantitative and qualitative features of the memory CD8 T cell pool
HRP20200439T1 (hr) Onkolitički adenovirus koji kodira protein b7
JP2017006118A (ja) 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用
AU2018277294A1 (en) Oncolytic virus and method
JP2026000910A (ja) 免疫回避腫瘍の処置
Cervera-Carrascon et al. Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.
CA3128350A1 (en) Microenvironment sensors to regulate engineered gene expression
JP2021511060A5 (https=)
Liang et al. Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity
WO2021259206A1 (zh) 针对sars-cov-2病毒的dna疫苗及其用途
Rossari et al. Gene-based delivery of immune-activating cytokines for cancer treatment
Berraondo et al. Immunocytokines and cytokine neutralization for cancer immunotherapy
Pistoia et al. Cytokines in neuroblastoma: from pathogenesis to treatment
Stewart et al. Chemokine–chemokine receptors in cancer immunotherapy
JP7827646B2 (ja) がん免疫療法に対する応答性を決定する方法
Mirbahari et al. Oncolytic Viruses Reshape PD‐1/PD‐L1 Signaling: Mechanisms and Clinical Synergy With Immune Checkpoint Blockade
Paul et al. The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer